^GSPC - S&P 500
| Previous Close | 2,670.71 |
| Open | 2,657.88 |
| Volume | 2,590,517,040 |
| Day's Range | 2,617.27 - 2,657.88 |
| 52 Week Range | 2,346.58 - 2,940.91 |
| Avg. Volume | 4,113,183,770 |
- Yahoo Finance Video•16 hours ago
Global X Fund's Jay Jacobs on China's economy
Yahoo Finance's Jackie DeAngelis discusses China's economy with Jay Jacobs, Global X Funds SVP and head of research and strategy.
- Yahoo Finance Video•18 hours ago
Existing home sales plummeted in December. Here's why.
Existing home sales saw a sharp decline in December, but this Wharton professor says real estate could pick up in 2019. Yahoo Finance's Adam Shapiro and Rick Newman discuss with Lending Tree Chief Economist Tendayi Kapfidze, Rosecliff CEO Mike Murphy, and Wharton School of Finance professor Susan Wachter.
- Reuters•9 minutes ago
US STOCKS-Futures rise on strong earnings reports from Dow members
Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019. ...
- MarketWatch•21 minutes ago
Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols
Shares of Rigel Pharmaceuticals Inc. shot up 9% in premarket trade Wednesday after the company announced it had entered a license and supply agreement with Spain-based Grifols, S.A. to commercialize fostamatinib disodium hexahydrate, its treatment for thrombocytopenia in adult patients. It is commercially available in the U.S. under the brand name Tavalisse. Under the terms of the agreement, Rigel will receive a $30 million upfront cash payment, with a potential $297.5 million in payments upon reaching certain regulatory and commercial milestones. That figure includes a potential $20 million payment upon the European Medicines Agency approving fostamatinib for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Rigel will also receive royalty payments based on tiered net sales, which the company said could reach 30% of net sales. In return, Grifols will receive exclusive rights to fostamatinib in Europe and Turkey. However, if fostamatinib has not been approved by the EMA for the treatment of ITP by 2021, Grifols will have the option to terminate the entire agreement, the companies said, and Rigel will have to pay Grifols $25 million to regain all rights to fostamatinib in Europe and Turkey. Rigel shares have fallen 12% in the year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 12.7%. The S&P 500 has gained 5%.
- TheStreet.com•26 minutes ago
An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon
At a surface level, it doesn't seem too difficult to figure out what happened in trading Tuesday. All the good had been priced in last week, as headlines had made the rounds stating that China had made sizable concessions on trade in an effort to get the ball rolling with President Trump.
- CNBC•27 minutes ago
Global slowdown could push US economy into recession this year, JP Morgan Asset Management warns
One of Wall Street's largest investing firms warns that a global growth slowdown could sink the U.S. into recession this year. According to J.P. Morgan Asset Management's Ben Mandel, it's a risk pushing the firm to turn cautious on stock markets here and abroad. Weak economic figures in China and lower growth estimates from the International Monetary Fund stirred up global slowdown fears and sent stocks lower Tuesday.
- MarketWatch•27 minutes ago
Kimberly-Clark shares slide after earnings miss
Kimberly-Clark Corp. shares fell 2.2% in Wednesday premarket trading after the consumer goods company reported earnings that missed estimates. Net income totaled $411 million, or $1.18 per share, down from $617 million, or $1.75 per share, for the same period last year. Adjusted EPS was $1.60, missing the $1.65 FactSet consensus. Sales totaled $4.57 billion, down 1% from $4.60 billion last year but ahead of the $4.45 billion FactSet consensus. Sales in the personal care segment fell while the K-C Professional segment sales rose. Kimberly-Clark expects 2019 sales to fall 1% to 2% from $18.49 billion in 2018. Adjusted EPS is expected to be $6.50 to $7.50. The FactSet consensus is for sales of $18.36 billion and EPS of $6.66. Kimberly-Clark shares have lost 2.2% in the past year while the S&P 500 index is down 7.3% for the period.
- Financial Times•36 minutes ago
[$$] Asia stocks fall on global growth and US-China trade worries
The Topix in Tokyo was off 0.8 per cent with only the telecoms and utilities segments holding in positive territory and as energy stocks fell 2.2 per cent. In Sydney, the S&P/ASX 200 was down 0.1 per cent with a 1.1 decline for energy stocks and a 0.8 per cent fall for the mining segment. Oil prices have come under pressure amid “concerns over global economic growth amid renewed trade tensions”, said Soni Kumari, an analyst at ANZ.
- MarketWatch•37 minutes ago
Here’s why hedge-fund billionaire Dalio says the next downturn is what ‘scares me most’
A lack of ammunition when it comes to monetary policy and growing political and social divides means the next economic downturn could get ugly, and that’s what worries hedge-fund titan Ray Dalio the most, he says.
- MarketWatch•38 minutes ago
Maybe investors should take Davos doom and gloom as good sign, says Guggenheim’s Minerd
Executives gathering in Davos this year are a pretty gloomy bunch, and that might be a bullish sign for stocks in the near term, says Guggenheim’s Scott Minerd.
Bloomberg•43 minutes agoStocks Gain as Traders Eye Earnings; Dollar Drops: Markets Wrap
The yen slid as the Bank of Japan cut its inflation outlook. The Stoxx Europe 600 Index reversed an early decline as a positive report from Carrefour SA boosted retailers. “Risk premia are quite high, so I think the markets are pricing quite a lot of uncertainty -- and probably too much uncertainty on the economic front, which is why we’ve seen this recent rally,” said Peter Oppenheimer, chief global equity strategist at Goldman Sachs Group Inc.
- MarketWatch•44 minutes ago
Tesla shares fall premarket after RBC downgrade
Tesla Inc. shares fell 1.3% in premarket trade Wednesday, after RBC downgraded the stock to underperform from outperform and said growth expectations are too high to justify current levels or add to positions. Analyst Joseph Spak cut his stock price target to $245 from $290. For years, Tesla has been selling a dream of transportation disruption and strong growth, turning the stock into a top 6, or even at times top 3 most valuable car original equipment manufacturer, despite delivering only a fraction of units promised and barely a profit, he wrote. "A stock should of course discount future cash flows and the market took the promises of Tesla and their future growth potential to justify lofty valuations while Tesla took capital needed to support their endeavors," Spak wrote in a ntoe. Now, however, "the rubber appears to be hitting the road," as the reality of Tesla becoming a high volume manufacturer with the scale and high average selling prices/margins are coming to a head, he said. Spak believes demand for Model 3 sedans is strongest at the $35K level the company had promised but that it has been unable to deliver yet. RBC is expecting that the company's third-quarter, when it posted a profit, may have been peak profitability for the decade. Shares have fallen 15% in the last 12 months, while the S&P 500 has fallen 7.3%.
- MarketWatch•45 minutes ago
Synchrony's stock soars after Walmart's Sam's Club partnership extended, earnings beat expectations
Shares of Synchrony Financial shot up 10% in premarket trade Wednesday, after the consumer financial services company said it extended its partnership with Walmart Inc.'s Sam's Club, and reported fourth-quarter earnings that beat expectations. As part of the Sam's Club partnership, Synchrony will keep managing and servicing the credit card programs. Synchrony also said it reached agreement to sell the Walmart loan portfolio it currently services, and Walmart has agreed to dismiss its lawsuit against Synchrony. For earnings, net income rose to $783 million, or $1.09 a share, from $385 million, or 49 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.09, above the FactSet consensus of 91 cents. Net interest income increased 11% to $4.33 billion, topping the FactSet consensus of $4.28 billion. The stock has declined 10.2% over the past three months through Tuesday, while the S&P 500 has lost 3.9%.
- MarketWatch•49 minutes ago
P&G shares rise after earnings beat
The Procter & Gamble Co. shares rose 2.8% in Wednesday premarket trading after the consumer goods company reported fiscal second-quarter earnings and sales that beat expectations. Net income totaled $3.2 billion, or $1.22 per share, up from $2.5 billion, or 93 cents per share, for the same period last year. Adjusted EPS was $1.25, ahead of the FactSet consensus for $1.21. Sales of $17.44 billion were up from $17.40 billion last year and exceeded the $17.16 billion FactSet consensus. Sales in the beauty and fabric & home care divisions rose while baby, feminine & family care and grooming sales fell. P&G raised the high end of its fiscal 2019 organic sales growth guidance by 1%, and now expects a range of 2% to 4% growth from $66.83 billion in 2018. P&G still expects adjusted EPS growth of 3% to 8% from the fiscal 2018 total of $4.22. The FactSet consensus is for sales of $66.72 billion and EPS of $4.40. P&G shares have gained 1.6% over the past year while the S&P 500 index has fallen 7.3% for the period.
Reuters•50 minutes agoInvestors shun stocks, seek safety in bonds as economic gloom spreads
Renewed concerns about a global economic slowdown continued to sap investor appetite for assets considered risky, dragging global stocks and bond yields lower on Wednesday, while the U.S. dollar held near three-week highs. Trading was choppy overnight as hopes of more stimulus measures from China to shore up economic growth clashed with worries over progress between Washington and Beijing to resolve a trade spat between the world's top two economies. The mood soured overnight after a report in the Financial Times that the Trump administration had rejected an offer from China for preparatory trade talks this week ahead of high-level negotiations scheduled for next week.
Associated Press•54 minutes agoWorld markets cautious on worries over US-China talks
SINGAPORE (AP) — World stock markets were subdued Wednesday as news of possible hiccups in U.S.-China trade talks ratcheted up growth worries.
Reuters•55 minutes agoInvestors shun stocks, seek safety in bonds as economic gloom spreads
Renewed concerns about a global economic slowdown continued to sap investor appetite for assets considered risky, dragging global stocks and bond yields lower on Wednesday, while the U.S. dollar held near three-week highs. Trading was choppy overnight as hopes of more stimulus measures from China to shore up economic growth clashed with worries over progress between Washington and Beijing to resolve a trade spat between the world's top two economies. The mood soured overnight after a report in the Financial Times that the Trump administration had rejected an offer from China for preparatory trade talks this week ahead of high-level negotiations scheduled for next week.
- CNBC•59 minutes ago
Bill Gates: My 'best investment' turned $10 billion into $200 billion worth of economic benefit
Investing in global health organizations aimed at increasing access to vaccines creates a 20-to-1 return, the Microsoft co-founder and philanthropist says. Investing in global health organizations aimed at increasing access to vaccines creates a 20-to-1 return in economic benefit, billionaire Microsoft MSFT co-founder and philanthropist Bill Gates told CNBC on Wednesday. Over the past two decades, the Bill and Melinda Gates Foundation has donated "a bit more than $10 billion" into mainly three groups: The Global Alliance for Vaccines and Immunization, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Global Polio Eradication Initiative.
- MarketWatch•1 hour ago
United Tech stock soars 4% premarket after earnings blow past estimates
United Technologies Corp. shares jumped 4% in premarket trade Wednesday, after the company blew past earnings estimates for the fourth quarter and offered upbeat guidance for 2019. The company said it had net income of $686 million, or 83 cents a share, in the quarter, up from $397 million, or 50 cents a share, in the year-earlier period. Adjusted per-share earnings came to $1.95, well ahead of the FactSet consensus of $1.55. Sales rose to $18.0 billion from $15.7 billion, also well ahead of the FactSet consensus of $16.8 billion. "Looking to 2019, our segment profit is expected to grow faster than sales, and free cash flow, excluding separation costs, is expected to grow faster than earnings," Chief Executive Greg Hayes said in a statement. The company, which is planning to split into three global companies housing its core businesses, said it now expects 2019 adjusted EPS of $7.70 to $8.00, compared with a $7.81 FactSet consensus. Sales are expected to range from $75.5 billion to $77.0 billion, compared with a FactSet consensus of $76.6 billion. Shares have fallen 18.4% in the last 12 months, while the S&P 500 has fallen 7.3% and the Dow Jones Industrial Average has fallen 6.9%.
- CNBC•1 hour ago
Nobel winner Robert Shiller says there's still a risk of a full-blown bear market
"There is a feeling that the stock market might be due for some deflating now because it's been a long time, and we've seen some hints of it and we haven't seen the real deflation yet," he told CNBC at the World Economic Forum (WEF) in Davos, Switzerland. U.S. stock markets may have recovered slightly from sharp falls at the end of last year, but there's still a risk of a significant downward trend, Robert Shiller, a professor of economics at Yale University and a Nobel laureate, told CNBC Wednesday.
- Barrons.com•1 hour ago
Dow Futures Gain 70 Points Despite Everything
Gloomy headlines about trade and economic growth aren’t pulling the market lower Wednesday morning. Credit earnings?
